Kynurenine and depressive symptoms in a poststroke population

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1827-1835

  Bensimon, Kira ^a,b   Herrmann, Nathan ^a,b,d   Swardfager, Walter ^a,d   Yi, Hao ^a   Black, Sandra E ^a,d   Gao, Fu Qiang ^a,d   Snaiderman, Abraham ^b,c   Lanctôt, Krista L ^a,d  

^a Sunnybrook Health Sciences Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO REHABILITATION INSTITUTE   (Canada)

^d HEART AND STROKE FOUNDATION OF CANADA   (Canada)

Author keywords

Cytokine; Depression; Inflammation; Kynurenine; Stroke; Tryptophan

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; KYNURENINE; TRYPTOPHAN; TUMOR NECROSIS FACTOR;

AGED; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; OBESITY; OBSERVATIONAL STUDY; OXIDATIVE STRESS; RISK FACTOR; SMOKING; SYMPTOMATOLOGY;

EID: 84908215913     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S65740     Document Type: Article

References (65)

1. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke. 2005;36:1330–1340.
2. Ayerbe L, Ayis S, Wolfe CD, Rudd AG. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry. 2013;202:14–21.
3. Whyte EM, Mulsant BH, Vanderbilt J, Dodge HH, Ganguli M. Depression after stroke: a prospective epidemiological study. J Am Geriatr Soc. 2004;52:774–778.
4. Chen Y, Patel NC, Guo JJ, Zhan S. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22: 159–166.
5. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–457.
6. Fujigaki S, Saito K, Sekikawa K, et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol. 2001;31:2313–2318.
7. Pemberton LA, Kerr SJ, Smythe G, Brew BJ. Quinolinic acid production by macrophages stimulated with IFN-gamma TNF-alpha and IFN-alpha. J Interferon Cytokine Res. 1997;17:589–595.
8. Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, Stone TW. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci. 2007;26:2211–2221.
9. Gabbay V, Liebes L, Katz Y, et al. The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:37–44.
10. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98:143–151.
11. Riedel WJ, Klaassen T, Schmitt JA. Tryptophan, mood, and cognitive function. Brain Behav Immun. 2002;16:581–589.
12. Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:94.
13. Swardfager W, Herrmann N, Dowlati Y, et al. Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease. Psychoneuroendocrinology. 2009;34:1560–1566.
14. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316–318.
15. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012;32: 1677–1698.
16. Swardfager W, Winer DA, Herrmann N, Winer S, Lanctôt KL. Interleukin-17 in post-stroke neurodegeneration. Neurosci Biobehav Rev. 2013;37:436–444.
17. Dhabhar FS, Burke HM, Epel ES, et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res. 2009;43:962–969.
18. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5:401–412.
19. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21:199–206.
20. Maes M, Song C, Lin AH, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology. 1999;20:370–379.
21. Basic Kes V, Simundic AM, Nikolac N, Topic E, Demarin V. Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem. 2008;41:1330–1334.
22. Kim JM, Stewart R, Kim SW, et al. Associations of cytokine gene polymorphisms with post-stroke depression. World J Biol Psychiatry. 2012;13:579–587.
23. Liesz A, Suri-Payer E, Veltkamp C, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15:192–199.
24. Su JA, Chou SY, Tsai CS, Hung TH. Cytokine changes in the pathophysiology of poststroke depression. Gen Hosp Psychiatry. 2012; 34:35–39.
25. Yang L, Zhang Z, Sun D, Xu Z, Zhang X, Li L. The serum interleukin-18 is a potential marker for development of post-stroke depression. Neurol Res. 2010;32:340–346.
26. Bossù P, Salani F, Cacciari C, et al. Disease outcome alexithymia and depression are differently associated with serum IL-18 levels in acute stroke. Curr Neurovasc Res. 2009;6:163–170.
27. Jiménez I, Sobrino T, Rodríguez-Yáñez M, et al. High serum levels of leptin are associated with post-stroke depression. Psychol Med. 2009;39: 1201–1209.
28. Ormstad H, Aass HC, Amthor K, Lund-Sørensen N, Sandvik L. Serum levels of cytokines, glucose, and hemoglobin as possible predictors of poststroke depression, and association with poststroke fatigue. Int J Neurosci. 2012;122:682–690.
29. Ormstad H, Aass HC, Amthor KF, Lund-Sørensen N, Sandvik L. Serum cytokine and glucose levels as predictors of poststroke fatigue in acute ischemic stroke patients. J Neurol. 2011;258:670–676.
30. Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB. The Stroke Data Bank: design methods and baseline characteristics. Stroke. 1988;19:547–554.
31. [No authors listed]. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol. 1988;41:105–114.
32. Radloff LS. The CES-D scale: a self-report depression scaled for research in the general population. Appl Psychol Meas. 1977;1:385–401.
33. Kunitz SC, Gross CR, Heyman A, et al. The pilot Stroke Data Bank: definition, design, and data. Stroke. 1984;15:740–746.
34. Agrell B, Dehlin O. Comparison of six depression rating scales in geriatric stroke patients. Stroke. 1989;20:1190–1194.
35. Morris PL, Robinson RG, de Carvalho ML, et al. Lesion characteristics and depressed mood in the stroke data bank study. J Neuropsychiatry Clin Neurosci. 1996;8:153–159.
36. Ramasubbu R, Flint A, Brown G, Awad G, Kennedy S. A neuroendocrine study of serotonin function in depressed stroke patients compared to non depressed stroke patients and healthy controls. J Affect Disord. 1999;52:121–133.
37. Ramasubbu R, Robinson RG, Flint AJ, Kosier T, Price TR. Functional impairment associated with acute poststroke depression: the Stroke Data Bank Study. J Neuropsychiatry Clin Neurosci. 1998;10:26–33.
38. Parikh RM, Eden DT, Price TR, Robinson RG. The sensitivity and specificity of the Center for Epidemiologic Studies Depression Scale in screening for post-stroke depression. Int J Psychiatry Med. 1988;18:169–181.
39. Shinar D, Gross CR, Price TR, Banko M, Bolduc PL, Robinson RG. Screening for depression in stroke patients: the reliability and validity of the Center for Epidemiologic Studies Depression Scale. Stroke. 1986;17:241–245.
40. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
41. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922–935.
42. Brott T, Marler JR, Olinger CP, et al. Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke. 1989;20: 871–875.
43. Williams LS, Yilmaz EY, Lopez-Yunez AM. Retrospective assessment of initial stroke severity with the NIH Stroke Scale. Stroke. 2000;31: 858–862.
44. Anderson GM, Purdy WC. Liquid chromatographic-fluorometric system for the determination of indoles in physiological samples. Anal Chem. 1979;51:283–286.
45. Forrest CM, Mackay GM, Stoy N, et al. Tryptophan loading induces oxidative stress. Free Radic Res. 2004;38:1167–1171.
46. Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. Stroke. 2005;36: 2296–2301.
47. Kubera M, Kenis G, Bosmans E, Scharpe S, Maes M. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology. 2000;23:89–98.
48. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem. 2004;37:684–687.
49. Frazer A, Pandey GN, Mendels J. Metabolism of tryptophan in depressive disease. Arch Gen Psychiatry. 1973;29:528–535.
50. Møller SE, Kirk L, Honoré P. Tryptophan tolerance and metabolism in endogenous depression. Psychopharmacology (Berl). 1982;76:79–83.
51. Wood K, Harwood J, Coppen A. The effect of antidepressant drugs on plasma kynurenine in depressed patients. Psychopharmacology (Berl). 1978;59:263–266.
52. Nozaki K, Beal MF. Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab. 1992;12:400–407.
53. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002;303:1–10.
54. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185:3190–3198.
55. Gigler G, Szenasi G, Simo A, et al. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol. 2007;564:116–122.
56. Brouns R, Verkerk R, Aerts T, et al. The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke. Neurochem Res. 2010;35:1315–1322.
57. Gold AB, Herrmann N, Swardfager W, et al. The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. J Neuroinflammation. 2011;8:17.
58. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.
59. Maes M, Galecki P, Verkerk R, Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett. 2011;32:264–273.
60. De Vries J, Van der Steeg AF, Roukema JA. Psychometric properties of the Fatigue Assessment Scale (FAS). Int J Clin Health Psychol. 2010;10:125–139.
61. Vestergaard S, Nayfield SG, Patel KV, et al. Fatigue in a representative population of older persons and its association with functional impairment, functional limitation, and disability. J Gerontol A Biol Sci Med Sci. 2009;64:76–82.
62. Ormstad H, Verkerk R, Amthor KF, Sandvik L. Activation of the kynurenine pathway in the acute phase of stroke and its role in fatigue and depression following stroke. J Mol Neurosci. Epub 2014 Mar 25.
63. Mackay GM, Forrest CM, Stoy N, et al. Tryptophan metabolism and oxidative stress in patients with chronic brain injury. Eur J Neurol. 2006;13:30–42.
64. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood–brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007–2017.
65. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry. 2010;15:393–403.